Maze Therapeutics (NASDAQ:MAZE) Stock Price Expected to Rise, HC Wainwright Analyst Says

Key Points

• HC Wainwright raised the price target for Maze Therapeutics from $34.00 to $50.00, suggesting a potential upside of 101.61% from its current price and maintaining a "buy" rating on the stock.
• Other analysts, such as BTIG Research and Wall Street Zen, have also issued positive ratings; the consensus rating for Maze Therapeutics is currently a "Buy" with an average price target of $30.17.
• Maze Therapeutics recently reported its quarterly earnings, exceeding expectations with an EPS of ($0.77), slightly higher than the consensus estimate of ($0.79).

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) had its price target lifted by stock analysts at HC Wainwright from $34.00 to $50.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price objective would suggest a potential upside of 101.61% from the company's current price.

Other research analysts have also recently issued research reports about the stock. BTIG Research lifted their target price on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a research note on Friday. Wall Street Zen upgraded shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Finally, Wedbush began coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat.com, Maze Therapeutics presently has a consensus rating of "Buy" and an average price target of $30.17.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $24.80 on Friday. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $25.50. The company has a 50-day moving average price of $15.04 and a two-hundred day moving average price of $12.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Alphabet Inc. acquired a new position in shares of Maze Therapeutics during the 1st quarter worth about $26,561,000. Invesco Ltd. acquired a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $226,000. Bank of New York Mellon Corp acquired a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $190,000. Nuveen LLC acquired a new stake in shares of Maze Therapeutics during the 1st quarter worth approximately $125,000. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Maze Therapeutics during the 1st quarter worth approximately $1,376,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.